This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Your Calendar for Next Year's Event!
May 9-12, 2022Hynes Convention Center, Boston

John Rhoden, Ph.D.
Director, Preclinical Development at Fusion Pharmaceuticals


Dr. John Rhoden is the Senior Director of Nonclinical Development at Fusion Pharmaceuticals in Boston, MA.  He oversees nonclinical development activities, including PK/PD, toxicology, and bioanalysis, supporting Fusion’s pipeline of proprietary and partnered targeted alpha therapeutics.  Prior to Fusion. Dr. Rhoden worked in several roles in ADME/PK/PD and translational sciences at Eli Lilly and Company supporting biologics programs in oncology and immunology.  He is a proponent of applying quantitative tools and fit-for-purpose modeling to guide experimentation and decision making in complex situations.

Dr. Rhoden received his Ph.D. chemical engineering from the Massachusetts Institute of Technology and a B.S. in chemical engineering from North Carolina State University.

Agenda Sessions

  • ROOM 205B: Development of Targeted Alpha Therapeutics for the Treatment of Solid Tumors